Claire S. Whyte
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
Whyte, Claire S.; Morrow, Gael B.; Mitchell, Joanne L.; Chowdary, Pratima; Mutch, Nicola J.
Authors
Dr Gael Morrow g.morrow1@rgu.ac.uk
Chancellor's Fellow
Joanne L. Mitchell
Pratima Chowdary
Nicola J. Mutch
Abstract
The global pandemic of coronavirus disease 2019 (COVID‐19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D‐dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients.
Citation
WHYTE, C.S., MORROW, G.B., MITCHELL, J.L., CHOWDARY, P. and MUTCH, N.J. 2020. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. Journal of thrombosis and haemostasis [online], 18(7), pages 1548-1555. Available from: https://doi.org/10.1111/jth.14872
Journal Article Type | Review |
---|---|
Acceptance Date | Apr 21, 2020 |
Online Publication Date | Jul 3, 2020 |
Publication Date | Jul 31, 2020 |
Deposit Date | Aug 7, 2023 |
Publicly Available Date | Aug 15, 2023 |
Journal | Journal of thrombosis and haemostasis |
Print ISSN | 1538-7933 |
Electronic ISSN | 1538-7836 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 18 |
Issue | 7 |
Pages | 1548-1555 |
DOI | https://doi.org/10.1111/jth.14872 |
Keywords | Fibrin; Fibrinolysis; Plasminogen activator inhibitor 1; Respiratory distress syndrome (adult); SARS virus; Tissue plasminogen activator; COVID-19 |
Public URL | https://rgu-repository.worktribe.com/output/2034926 |
Files
WHYTE 2020 Fibrinolytic abnormalities (VOR)
(912 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
Copyright Statement
© 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
You might also like
Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1).
(2022)
Journal Article
Downloadable Citations
About OpenAIR@RGU
Administrator e-mail: publications@rgu.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search